Ad Hoc Committee report: systemic antibiotics for treatment of acne vulgaris: efficacy and safety.
D000152:Acne Vulgaris / Q000188:drug therapy*; D000293:Adolescent; D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002648:Child; D002981:Clindamycin / Q000009:adverse effects / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003707:Demeclocycline / Q000627:therapeutic use; D004917:Erythromycin / Q000627:therapeutic use; D005230:Fatty Acids, Nonesterified / Q000378:metabolism; D005260:Female; D006801:Humans; D008034:Lincomycin / Q000009:adverse effects / Q000627:therapeutic use; D008875:Middle Aged; D010919:Placebos; D011247:Pregnancy; D011425:Propionibacterium acnes / Q000187:drug effects; D013420:Sulfamethoxazole / Q000627:therapeutic use; D013752:Tetracycline / Q000627:therapeutic use; D013754:Tetracyclines / Q000009:adverse effects; D014295:Trimethoprim / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D005230:Fatty Acids, Nonesterified; D010919:Placebos; D013754:Tetracyclines; D002981:Clindamycin; D003707:Demeclocycline; D004917:Erythromycin; D014295:Trimethoprim; D008034:Lincomycin; D013752:Tetracycline; D013420:Sulfamethoxazole